- Supported exchanges /
- NASDAQ /
- ZVRA.NASDAQ
Zevra Therapeutics Inc. (ZVRA NASDAQ) stock market data APIs
$8
0.22(2.8%)
as of September 16, 2024
Price chart is built with Anychart
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Zevra Therapeutics Inc. Financial Data Overview
| 7.78 | |
| 8 | |
| - | |
| 8.18 | |
| 7.77 | |
| 3.89-8.44 | |
| 411 M | |
| 52 618 K | |
| 23 689 K | |
| -0.48 | |
| 1.952 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'ZVRA',
Type:
'Common Stock',
Name:
'Zevra Therapeutics Inc.',
Exchange:
'NASDAQ',
CurrencyCode:
'USD',
CurrencyName:
'US Dollar',
CurrencySymbol:
'$',
CountryName:
'USA',
CountryISO:
'US',
OpenFigi:
'BBG0026ZG1F5',
ISIN:
NULL,
CUSIP:
NULL,
CIK:
'1434647',
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
'2015-04-16',
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Biotechnology',
HomeCategory:
NULL,
IsDelisted:
false,
}
Zevra Therapeutics Inc. Fundamental Data is available in our Financial Data APIs
- Net Revenue 23 689 K
- EBITDA -70 829 000
- Earnings Per Share -1.71
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Zevra Therapeutics Inc. Earnings via APIs
- Latest Release 2024-08-13
- EPS/Forecast -0.44
Get Zevra Therapeutics Inc. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Zevra Therapeutics Inc. latest news via APIs
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial Results
Arimoclomol NDA resubmission remains on track for end of year filing Proposed acquisition of Acer Therapeutics on track to close Q4 2023 and will diversify Zevra’s revenue with FDA-approved OLPRUVA...
- EARNINGS RELEASES AND OPERATING RESULTS
- NASDAQ:ZVRA
- ZEVRA THERAPEUTICS
- ZVRA
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
